Dualsystems Biotech AG is testing the limits of the LRC-TriCEPSTM (CaptiRec) technology using antibodies with different affinities against the same target and cells expressing the target receptor with different expression levels.
Limits-of-LRC-TriCEPS
Details of the assesment see here
Dualsystems Biotech AG and Biaffin GmbH & Co KG perform together an example of an experiment.
In the case study Dualsystems Biotech AG determined the targets of the Anti EGFR antibodies and Biaffin GmbH& Co KG measured the binding characteristics of the ligand receptor interaction using Surface Plasmon Resonance (SPR).
Dualsystems Biotech AG Press Release
Zürich Switzerland – June 23, 2014 – Dualsystems Biotech AG offers the most advanced technology for identifying receptor(s) for orphan ligands. The ligand-receptor capture technology (LRC-TriCEPS) is an innovative and conceptually new approach for the unbiased discovery of cell surface interactions of ligands ranging from peptides, proteins, antibodies to viruses. Dualsystems offers the LRC-TriCEPS technology in our service line CaptiRec. We offer a variety of formats which will fit your needs: From CaptiRec Kits for your own in-house experiments to an all-inclusive CaptiRec Service.
Dualsystems Biotech AG is looking forward to support your project with the newest invention in receptor/target discovery.
Please watch the video where we explain how the LRC-TriCEPS technology works: LRC-TriCEPS-Video
Dualsystems Biotech AG Press Release
Schlieren, Switzerland, January 2014: – Dualsystems Biotech AG has announced it will collaborate with another Swiss laboratory, Institute for Biopharmaceutical Research (IBR Inc.) to validate the CaptiRec Triceps/Ligand Receptor Capture Technology. This technology is used to identify the Cell Membrane Receptors on Living Cells.
The partnership will combine the respective strengths of Dualsystems, a leading service provider for protein interaction at the cell membrane and IBR Inc., a GLP-compliant contract research organization specializing in cell-based assays
Dualsystems Biotech has closed a Series C financing round with support from existing and new investors to implement and drive forward its new business strategy in mass spectrometry based protein interaction discovery.
Dualsystems Biotech is driving its business activities towards new technologies and builds up new strengths in the field of protein interaction discovery.
